The 2-year CI of CCyR and MR4.5 in 128 patients treated with dasatinib as first line therapy according to the BCR-ABL1 transcript level at 3 (higher or lower than 10%) and 6 (higher or lower than 1%) months
| Transcript ratio . | n (%) . | CI of CCyR . | CI of MR4.5 . | |
|---|---|---|---|---|
| 3 mo . | 6 mo . | P < .001 . | P < .001 . | |
| <10% | <1% | 104 (81.3) | 100 | 52.9 |
| <10% | >1% | 14 (10.6) | 86.9 | 0 |
| >10% | <1% | 1 (0.8) | — | — |
| >10% | >1% | 9 (7) | 55.0 | 0 |
| Transcript ratio . | n (%) . | CI of CCyR . | CI of MR4.5 . | |
|---|---|---|---|---|
| 3 mo . | 6 mo . | P < .001 . | P < .001 . | |
| <10% | <1% | 104 (81.3) | 100 | 52.9 |
| <10% | >1% | 14 (10.6) | 86.9 | 0 |
| >10% | <1% | 1 (0.8) | — | — |
| >10% | >1% | 9 (7) | 55.0 | 0 |